Chemoradiation therapy in nonsmall cell lung cancer

Baas, Paul; Belderbos, J.; Heuvel, Michel van den

doi:10.1097/cco.0b013e328341eed6

Cited by 27 publications

(20 citation statements)

References 71 publications

(91 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the most important preventive approach is to reduce the radiation dose to the lung tissues. During concurrent chemoradiotherapy, radiation pneumonitis is effectively prevented by strengthening the limits of the dosimetric parameters for pulmonary radiotherapy 14–16. Similarly, by alleviating pulmonary damage due to thoracic radiotherapy, and thereby reducing the synergistic reaction between thoracic radiotherapy and erlotinib on lung tissue during concurrent therapy, it is theoretically possible to reduce the risk of radiation pneumonitis.…”

Section: Discussionmentioning

confidence: 99%

Preliminary analysis of the risk factors for radiation pneumonitis in patients with non- small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy

Zhuang¹,

Hou²,

Wang³

et al. 2014

OTT

View full text Add to dashboard Cite

PurposeThe aim of this study was to investigate radiation pneumonitis and its associated risk factors in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy.Materials and methodsWe conducted an analysis of patients with nonoperable stage IIIA–IV non-small-cell lung cancer who were treated with concurrent thoracic radiotherapy and erlotinib (ClinicalTrials.gov identifier: NCT00973310). The Common Terminology Criteria for Adverse Events version 3.0 grading system was applied to evaluate the incidence of radiation pneumonitis. The lung dosimetric parameters were recorded in accordance with the treatment plan, and the study endpoint was radiation pneumonitis at grade 2 or more.ResultsAmong the 24 selected clinical cases, nine were identified with radiation pneumonitis of grade 2 or above (37.5%). This included four cases with grade 2 (16.7%), two cases with grade 3 (8.3%), and three cases with grade 5 (12.5%). The results showed that the planning target volume was a significant factor affecting the incidence of radiation pneumonitis. All lung dosimetric parameters exhibited statistically significant differences between patients with pneumonitis and patients without pneumonitis. The receiver operating characteristic (ROC) curve analysis showed that all lung dosimetric parameters were useful in predicting the incidence of radiation pneumonitis. In addition, the threshold values of V5, V10, V15, V20, V30, and mean lung dose were >44%, >29%, >27%, >22%, >17% and >1,027 cGy, respectively.ConclusionSpecial attention should be paid to the adverse effects of radiation pneumonitis in concurrent thoracic radiotherapy and erlotinib treatment. Lung dosimetric parameters are important predictive factors in radiation pneumonitis.

show abstract

Section: Discussionmentioning

confidence: 99%

Preliminary analysis of the risk factors for radiation pneumonitis in patients with non- small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy

Zhuang¹,

Hou²,

Wang³

et al. 2014

OTT

View full text Add to dashboard Cite

show abstract

“…Standardized radiotherapy could kill the majority of tumor cells in a certain extent, but because of such factors as severe toxicity, resistant cells, the existence of cancer stem cells and anti-radiation cell, low immunity of advanced tumors patients and other factors, the implementation and benefit of the treatment program are greatly hampered (Levina et al, 2010;Baas et al, 2011;Hsu et al, 2011). Therefore, it is received widespread attention to explore and research new methods of treatment.…”

Section: Discussionmentioning

confidence: 99%

Moderating Effects and Maintenance of Lung Cancer Cellular Immune Functions by CIK Cell Therapy

Jin¹,

Chen²,

Li³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Aims: To study the CIK cell treatment effects on regulation of cellular immune function disorders in patients with lung cancer, and to analyze the time characteristics. Methods: Cellular immune function was assessed by FCM, and patients with functional disorders were randomly divided into two groups, one given CIK cell therapy within 18 months (5 courses) and the other the controls, which were followed up for 1 year with cellular immune functions tested once a month. Results: There were 5 types of cellular immunity, 4 of which are disorders; after CIK treatment, the improvement rate of the 4 groups were 79.1%, 70.8%, 76.0% and 70.0%, intergroup differences not being statistically significant (P=0.675), all significantly higher than in the control group (P=0.000). The median maintenance times for the 4 groups were 10.4 months (9.76-11.04), 8.4 months (7.86-8.94), 9.8 months (9.20-10.4) and 7.9 months (6.25-9.55), respectively. Conclusions: CIK cells were able to improve the immune functions of patients with lung cancer, the rate of improvement and maintenance time being related to the immune function before the treatment and CIK-cell-therapy courses.

show abstract

“…Patients with cancer usually have a poor prognosis, despite being subjected to surgery, chemotherapy or radiotherapy (19). Chemotherapy or radiotherapy may be useful to a certain extent; however, due to the high toxicity and other associated factors, the implementation and benefit of these treatments are largely hampered (20,21).…”

Section: Discussionmentioning

confidence: 99%

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

Pan

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Cytokine-induced killer (CIK) cells have been used as adoptive immunotherapy in cancer. The present study evaluated the effect of CIK cells on immune function in patients with lung cancer. Patients were divided into three groups, according to the treatment received prior to CIK cell treatment: CIK group (no prior treatment), Che-Sur group (prior chemotherapy and surgery) and Che-Rad group (prior chemotherapy and radiotherapy). Following treatment, the average percentage of cluster of differentiation (CD)3 + CD4 + , CD3 + , natural killer (NK) and NKT cells in peripheral blood was significantly higher than that prior to CIK treatment in the Che-Sur and CIK groups, and the levels of interferon-γ in serum were significantly higher than those prior to CIK treatment in the Che-Sur and CIK groups. On the contrary, the levels of interleukin-10 had decreased in these groups following CIK treatment. Subsequently, patients were divided into three groups according to the percentage of CD3 + CD56 + CIK cells that were administered to the patients. The number of NK and NKT cells increased with increasing number of CD3 + CD56 + cells. The patients in the CIK and Che-Sur groups were the most benefited ones following CIK treatment, contrarily to those in the Che-Rad group, since the increase in the number of CD3 + CD56 + CIK cells in the aforementioned patients enhanced the number of NK cells, which exhibit antitumor activity.

show abstract

Chemoradiation therapy in nonsmall cell lung cancer

Cited by 27 publications

References 71 publications

Preliminary analysis of the risk factors for radiation pneumonitis in patients with non- small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy

Preliminary analysis of the risk factors for radiation pneumonitis in patients with non- small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy

Moderating Effects and Maintenance of Lung Cancer Cellular Immune Functions by CIK Cell Therapy

Effect of cytokine-induced killer cells on immune function in patients with lung cancer

Contact Info

Product

Resources

About